Effect of combined therapy with piperazine ferulate and benazepdl on urinary albumin excretion rate in patients with early diabetic nephropathy
doi: 10.3969/j.issn.1006-0111.2013.01.014
- Received Date: 2012-03-08
- Rev Recd Date: 2012-07-07
-
Key words:
- piperazine ferulate /
- benazepdl /
- diabetic nephropathy /
- urinary albumin excretion rate
Abstract: To explore the effect of combined therapy with piperazine ferulate and benazepdl on urinary albumin excretion rate (UAER) in patients with early diabetic nephropathy (DN). Methods A total of 164 children were included in the study, 82 of whom accepted piperazine ferulate and benazepdl were put into the observed group, 82 of whom accepted only benazepdl were put into the control group. The difference of the UAER, 24 h urinary protein, Serum creatinine, blood glucose, glycosylated hemoglobin and CRP were compared by T test. Results ①After treatment, the UAER, 24 h urinary protein, CRP and blood pressure were significantly lower than that before treatment in both observed group and control group;②The UAER, 24 h urinary protein and CRP were significantly lower in the observed group than that of the control group after treatment. Conclusion Combined use of piperazine ferulate and benazepdl could significantly lower the levels of UAER in patients with early DN.
Citation: | TU Chuan-fa, WANG Li-jun, JIN Du, YANG Hong-wei, ZHANG You-you, MOU Xiao-yue. Effect of combined therapy with piperazine ferulate and benazepdl on urinary albumin excretion rate in patients with early diabetic nephropathy[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(1): 49-50,56. doi: 10.3969/j.issn.1006-0111.2013.01.014 |